AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 30549358
Drug: Concurrent cetuximab
RxNorm normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Concurrent cetuximab plus docetaxel
Trial: 26493812
Drug: Calcium carbonate
RxNorm normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Calcium carbonate 1 g/day
Trial: 19845414
Drug: Pharmacotherapy for
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacotherapy for symptomatic management (anxiety or insomnia)
Trial: 17203013
Drug: Haloperidol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (3 mg, oral) in pathological gamblers
Trial: 17203013
Drug: Haloperidol (3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (3 mg, oral) in non-gambler controls
Trial: 3602942
Drug: Acetyl salicylic
RxNorm normalized name: Acetyl salicylic acid specific IgE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acetyl salicylic acid (3 g daily for one week)
Trial: 3602942
Drug: Indomethacin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin (150 mg daily for one week)
Trial: 29233548
Drug: Actual weight-based
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Actual weight-based (AWB) chemotherapy dosing
Trial: 22554311
Drug: Fomepizole IV
RxNorm normalized name: Fomepizole
DrugBank: Fomepizole (DB01213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fomepizole IV or orally (7 mg/kg)
Trial: 22554311
Drug: Oral loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral loading doses of 10‐15 mg/kg, followed by supplemental doses of 3‐10 mg/kg/12 h through 96 hours
Trial: 20861293
Drug: Simvastatin 40
RxNorm normalized name: simvastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Simvastatin 40 mg at night
Trial: 12851773
Drug: Tolterodine extended-release
RxNorm normalized name: tolterodine Extended Release Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolterodine extended-release 4 mg once daily
Trial: 25297064
Drug: EF (3.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EF (3.0 g/L oligofructose)
Trial: 21288228
Drug: Intravenous remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous remifentanil bolus (0.4 μg/kg) administered immediately after a contraction trigger
Trial: 21288228
Drug: Intravenous remifentanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous remifentanil bolus (0.4 μg/kg) administered 140 seconds before the next contraction
Trial: 19262478
Drug: Aliskiren alone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aliskiren alone or in combination with a diuretic or a calcium channel blocker (CCB)
Trial: 11709518
Drug: Cisapride (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisapride (10 mg four times daily)
Trial: 3668983
Drug: Colchicine 1.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Colchicine 1.5 mg daily
Trial: 21664867
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bevacizumab (10 mg/kg every 2 weeks) and temsirolimus (25 mg weekly; group A)
Trial: 21664867
Drug: Sunitinib (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sunitinib (50 mg/day for 4 weeks followed by 2 weeks off; group B)
Trial: 21664867
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of interferon alfa (9 mIU three times per week) and bevacizumab (10 mg/kg every 2 weeks; group C)
Trial: 21664867
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of bevacizumab and temsirolimus (group A)
Trial: 21664867
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of interferon alfa and bevacizumab (group C)
Trial: 17537152
Drug: Atorvastatin (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Atorvastatin (20 mg day(-1))
Trial: 14982784
Drug: Indinavir 1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir 1000 mg every 12 h with nelfinavir (n = 10)
Trial: 14982784
Drug: Indinavir 1200
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indinavir 1200 mg every 12 h with nelfinavir (n = 7)
Trial: 14982784
Drug: Nelfinavir (in
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nelfinavir (in combination with indinavir 1000 mg every 12 h) (n = 9)
Trial: 11133744
Drug: Liposomal ATRA
RxNorm normalized name: ATRA
DrugBank: Tretinoin (DB00755)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Liposomal ATRA (90 mg/m(2) every other day until complete remission or a maximum of 56 days)
Trial: 9468068
Drug: Streptokinase or
RxNorm normalized name: dornase alfa / streptokinase Oral Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Streptokinase or combination therapy
Trial: 773601
Drug: Methacycline 600
RxNorm normalized name: Methacycline
DrugBank: Metacycline (DB00931)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methacycline 600 mg daily for 14 days
Trial: 773601
Drug: Ampicillin 2
RxNorm normalized name: ampicillin 250 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ampicillin 2 gm daily for 14 days
Trial: 31764258
Drug: Tablets, ring,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablets, ring, and injections (TRIO study)
Trial: 31764258
Drug: Vaginal products
RxNorm normalized name: Vaginal Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaginal products (ring, insert, film, and gel) (Quatro study)
Trial: 27319277
Drug: Both oral
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both oral and intravenous ibuprofen
Trial: 22052276
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) using 20% 5‐aminolevulinic acid solution (ALA) and blue light
Trial: 22052276
Drug: Photodynamic therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Photodynamic therapy (PDT) using ALA with blue light
Trial: 17215967
Drug: Glucometer-guided insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucometer-guided insulin injection
Trial: 10849057
Drug: RACM regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RACM regimen (rabeprazole 10 mg bid, amoxicillin 750 mg bid, clarithromycin 200 mg bid, metronidazole 250 mg bid)
Trial: 10849057
Drug: RAC regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RAC regimen (rabeprazole 10 mg bid, amoxicillin 750 mg bid, clarithromycin 200 mg bid)
Trial: 9107431
Drug: 125 mg
RxNorm normalized name: niacin 125 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mg of oltipraz daily
Trial: 9107431
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of oltipraz weekly
Trial: 8260183
Drug: Local treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Local treatment only
Trial: 8260183
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of surgery, radiotherapy and hormone therapy
Trial: 8260183
Drug: Aggressive local
RxNorm normalized name: docusate calcium / phenolphthalein Oral Capsule [Docal]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aggressive local treatment with hormone therapy
Trial: 29397594
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine treatment with polyene phosphatidylcholine capsules)
Trial: 27509606
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of lipoic acid (0.6 g) and alprostadil (10 mg)
Trial: 10321449
Drug: Moxonidine (antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine (antihypertensive doses)
Trial: 10321449
Drug: Moxonidine (non-antihypertensive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Moxonidine (non-antihypertensive doses)
Trial: 10321449
Drug: Sympathicolytic agents
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sympathicolytic agents
Trial: 7933259
Drug: Noninvasive therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Noninvasive therapy (exercise and medication)
Trial: 3202402
Drug: Methylprednisolone, 30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methylprednisolone, 30 mg/kg per dose, 4 doses every 6 hours
Trial: 10690822
Drug: Topical 0.01%
RxNorm normalized name: tretinoin topical 0.01% topical gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.01% mitomycin-C eye drops (n = 17)
Trial: 8243490
Drug: Cefpodoxime proxetil
RxNorm normalized name: Cefpodoxime Proxetil
DrugBank: Cefpodoxime (DB01416)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cefpodoxime proxetil 200 mg every 12 h for 7 days
Trial: 8243490
Drug: Amoxicillin 500
RxNorm normalized name: amoxicillin 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amoxicillin 500 mg every 8 h for 7 days
Trial: 31108180
Drug: FeNO treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FeNO treatment algorithm
Trial: 26586093
Drug: Metronomic chemotherapy
RxNorm normalized name: menthol
DrugBank: Menthol (DB14123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metronomic chemotherapy with capecitabine and thalidomide after RFA
Trial: 27036656
Drug: Tat Oyi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tat Oyi vaccine (33 µg)
Trial: 27036656
Drug: Tat Oyi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tat Oyi vaccine (11 µg)
Trial: 27036656
Drug: Tat Oyi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tat Oyi vaccine (99 µg)
Trial: 27036656
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (0 µg Tat Oyi)
Trial: 22458392
Drug: Zinc sulfate
RxNorm normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Zinc sulfate (440 mg/day)
Trial: 19521723
Drug: Initial chemotherapy
RxNorm normalized name: brigatinib
DrugBank: Brigatinib (DB12267)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Initial chemotherapy for breast cancer
Trial: 16011670
Drug: H1 receptor
RxNorm normalized name: Histamine H1 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H1 receptor antagonists (H1RA)
Trial: 16011670
Drug: H2 receptor
RxNorm normalized name: Histamine H2 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: H2 receptor antagonists (H2RA)
Trial: 10367259
Drug: 740 mg/m2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 740 mg/m2 amifostine administered before chemotherapy
Trial: 10367259
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received 2.6 g/m2 5-fluorouracil and 500 mg/m2 folinic acid per week for 6 weeks
Trial: 7586593
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg of methimazole per day
Trial: 7586593
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg of methimazole per day
Trial: 1934382
Drug: Tranexamic acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tranexamic acid (10 mg/kg over 30 minutes followed by 1 mg.kg‐1.hr‐1 for 12 hours)
Trial: 1934382
Drug: Desmopressin (0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Desmopressin (0.3 micrograms/kg over 20 minutes after protamine infusion)
Trial: 1934382
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of tranexamic acid and desmopressin
Trial: 30592459
Drug: Whole cell
RxNorm normalized name: pertussis, whole cell
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Whole cell pneumococcal vaccine (WCV)
Trial: 24534139
Drug: Enhanced Internet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enhanced Internet treatment
Trial: 22367657
Drug: Levetiracetam (500-2000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Levetiracetam (500-2000 g/d)
Trial: 17685090
Drug: Astaxanthin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astaxanthin supplementation (2 capsules of 4 mg daily)
Trial: 17685090
Drug: Placebo (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (2 identical-looking capsules)
Trial: 10626717
Drug: Isobaric 9.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isobaric 9.75 mg bupivacaine
Trial: 10626717
Drug: Hyperbaric 9.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hyperbaric 9.75 mg bupivacaine
Trial: 10626717
Drug: Epidural injections
RxNorm normalized name: epidermal growth factor
DrugBank: Nepidermin (DB14145)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural injections of 3 ml lidocaine 2%
Trial: 21527171
Drug: Nutritional supplementation
RxNorm normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nutritional supplementation (energy and protein enriched diet, oral nutritional support, calcium‐vitamin D supplement, telephone counseling by a dietitian) for 3 months postdischarge
Trial: 11885181
Drug: Non-coated implants
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-coated implants
Trial: 11885181
Drug: All implants
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All implants in bone qualities 1 and 2 (BQ-1 and BQ-2)
Trial: 11885181
Drug: All implants
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All implants in bone qualities 3 and 4 (BQ-3 and BQ-4)
Trial: 1396838
Drug: Oral anticoagulant
RxNorm normalized name: CPDA-1 Anticoagulant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral anticoagulant therapy with warfarin (n = 102)
Trial: 1396838
Drug: Dipyridamole and
RxNorm normalized name: Dipyridamole
DrugBank: Dipyridamole (DB00975)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dipyridamole and aspirin (n = 130)
Trial: 29275333
Drug: Adalimumab (24
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adalimumab (24 mg/m2 for patients <13 years, 40 mg for others) administered subcutaneously every other week.
Trial: 23993735
Drug: Sufentanil 0.2
RxNorm normalized name: ropivacaine-sufentanil 0.2%-1 mcg/mL-NaCl 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 0.2 ng/ml
Trial: 23993735
Drug: Sufentanil 0.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 0.4 ng/ml
Trial: 23993735
Drug: Sufentanil 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sufentanil 0.5 ng/ml
Trial: 20883738
Drug: DTaP 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP 0.2 ml
Trial: 20883738
Drug: DTaP 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP 0.5 ml
Trial: 20883738
Drug: DTaP 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DTaP 0.2 ml and DTaP 0.5 ml
Trial: 17653013
Drug: Amiodarone treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiodarone treatment (900 mg/day intravenously for the first 2 days, then 600 mg/day)
Trial: 14698516
Drug: Neem (Azadirachta
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neem (Azadirachta indica) leaf extract dental gel (25 mg/g)
Trial: 11696124
Drug: Dexamethasone plus
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone plus low-dose ondansetron (50 microg.kg(‐1) ondansetron i.v.)
Trial: 9263718
Drug: Non-invasive diagnosis
RxNorm normalized name: Tavist Non-Sedating
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-invasive diagnosis and conservative treatment
Trial: 8427724
Drug: Ondansetron (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (16 mg) orally three times daily starting 24 hours after cisplatin
Trial: 8427724
Drug: Placebo orally
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo orally three times daily starting 24 hours after cisplatin
Trial: 8427724
Drug: Ondansetron (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ondansetron (16 mg)
Trial: 27743903
Drug: rexlemestrocel-L 150×10^6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rexlemestrocel-L 150×10^6
Trial: 27743903
Drug: rexlemestrocel-L 300×10^6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rexlemestrocel-L 300×10^6
Trial: 21996146
Drug: Prasugrel therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel therapy (loading dose 60 mg; maintenance dose 5 mg/day for patients ≥75 years old or ≤60 kg; 10 mg/day for others)
Trial: 16294652
Drug: Active management
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active management with medication or referral to a mental health specialist
Trial: 12450703
Drug: MMR/V vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR/V vaccine
Trial: 8734231
Drug: 0.375% bupivacaine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.375% bupivacaine, 0.6 mL.kg‐1 intraperitoneally
Trial: 1721980
Drug: Carvedilol (25-50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Carvedilol (25-50 mg once daily)
Trial: 1721980
Drug: Hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide (HCTZ) (25-50 mg once daily)
Trial: 31126570
Drug: Vaccinium arctostaphylos
RxNorm normalized name: Arctostaphylos tomentosa whole extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccinium arctostaphylos berry extract (400 mg capsule, three times daily for 3 months)
Trial: 27755056
Drug: Laryngoscope-assisted lightwand
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Laryngoscope-assisted lightwand technique (group L, n = 82)
Trial: 22479361
Drug: High-dose vitamin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose vitamin A (200,000 IU) in addition to daily low-dose vitamin A (5000 IU) for 15 days.
Trial: 22479361
Drug: Placebo in
RxNorm normalized name: placebo INTRAVEN VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo in addition to daily low-dose vitamin A (5000 IU) for 15 days.
Trial: 19017676
Drug: Higher dose
RxNorm normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher dose exercise programme (60 min/day) conducted whilst standing
Trial: 19017676
Drug: Lower dose
RxNorm normalized name: flowers
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lower dose exercise programme (30 min/day) primarily conducted whilst seated/supine
Trial: 17515696
Drug: Cinacalcet HCl
RxNorm normalized name: cinacalcet HCl
DrugBank: Cinacalcet (DB01012)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cinacalcet HCl (90 mg) following a high-fat, high-caloric meal
Trial: 17515696
Drug: Cinacalcet HCl
RxNorm normalized name: cinacalcet HCl
DrugBank: Cinacalcet (DB01012)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cinacalcet HCl (90 mg) following a low-fat, low-caloric meal
Trial: 17515696
Drug: Cinacalcet HCl
RxNorm normalized name: cinacalcet HCl
DrugBank: Cinacalcet (DB01012)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cinacalcet HCl (90 mg) under fasting conditions
Trial: 17515696
Drug: Cinacalcet HCl
RxNorm normalized name: cinacalcet HCl
DrugBank: Cinacalcet (DB01012)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cinacalcet HCl (90 mg) following high-fat meal
Trial: 17515696
Drug: Cinacalcet HCl
RxNorm normalized name: cinacalcet HCl
DrugBank: Cinacalcet (DB01012)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cinacalcet HCl (90 mg) following low-fat meal
Trial: 17515696
Drug: Cinacalcet HCl
RxNorm normalized name: cinacalcet HCl
DrugBank: Cinacalcet (DB01012)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Cinacalcet HCl (90 mg) across all treatment conditions
Trial: 10869738
Drug: No further
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No further treatment (no boost)
Trial: 9184703
Drug: Glimepiride 3
RxNorm normalized name: glimepiride 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 3 mg twice daily
Trial: 9184703
Drug: Glimepiride 6
RxNorm normalized name: glimepiride 6 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glimepiride 6 mg once daily
Trial: 1589410
Drug: Nasal spray
RxNorm normalized name: Nasal Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal spray formulation without STDHF
Trial: 1589410
Drug: Nasal formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal formulations containing 3% (w/v) of STDHF
Trial: 1589410
Drug: Nasal formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal formulations containing 1.65% (w/v) of STDHF
Trial: 1589410
Drug: Nasal formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal formulations containing 1.2% (w/v) of STDHF
Trial: 1589410
Drug: Nasal formulations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal formulations containing 0.8% (w/v) of STDHF
Trial: 1589410
Drug: All STDHF-containing
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All STDHF-containing sprays
Trial: 27893539
Drug: Pulsed Dye
RxNorm normalized name: amaranth dye
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulsed Dye Laser (PDL) treatment